Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

UroGen Pharma (URGN) stock in plain English

Free brief · no signupStart here
URGNPublished Nov 18, 2026
UroGen Pharma Ltd
Healthcare · Biotechnology
Sells Jelmyto, a specialized gel chemotherapy for non-muscle invasive upper tract urothelial cancer. Develops similar localized drug delivery treatments for recurring bladder cancers.
Assets:
Jelmyto gelFDA-approved therapy for upper tract urothelial cancer
RTGel platformProprietary reverse-thermal hydrogel formulation technology
Dual headquartersOperational facilities in Princeton, New Jersey and Israel
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
+6.51%$31.73
$1.56B
n/a (loss)
$250.21M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was URGN. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does UroGen Pharma (URGN) do?

UroGen Pharma Ltd (URGN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells Jelmyto, a specialized gel chemotherapy for non-muscle invasive upper tract urothelial cancer. Develops similar localized drug delivery treatments for recurring bladder cancers. Develops hydrogel medicines that turn liquid when chilled and solidify at body temperature to treat urinary cancers. It is worth $1.56B on the market and sold $250.21M over the last year.

Market cap
$1.56B
P/E ratio
None (reported a loss)
Annual sales
$250.21M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

Brands and businesses behind URGN

  • Jelmyto: Generates revenue by selling a prescription gel that delivers chemotherapy directly into the kidneys and urinary tract.

URGN’s flags, in plain English

Each flag is a number from UroGen Pharma’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Wide Gross Margin

Gross margin of 91.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 56.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Stupid Cash

Can pay this year's bills 3.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Burning Cash

Losing money, profit margin of -26.3%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about URGN

How big is UroGen Pharma?

UroGen Pharma’s market cap is $1.56B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $250.21M: what customers paid the company over the last year, before any costs.

What is URGN’s P/E ratio?

URGN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with URGN?

The business relies on a single commercial product, Jelmyto, for almost all of its product revenue. That is one risk on UroGen Pharma’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From UroGen Pharma’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. URGN’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card